Flow Cytometry Instruments and Reagents
The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The lawsuit touched off a series of legal conflicts between the companies. The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson.
BD is a global medical technology company that is advancing the world of health™.
The next evolution of efficiency and endurance for mountain running. BD mountain athletes Joe Grant and Kelly Halpin guide us through their picks for trail running. BD mountain athletes Joe Grant and Kelly Halpin guide us through their picks for trail…
Siemens Healthineers
Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news. Elevate your spectral data with built‑in standardization Designed and validated for use with cell suspensions, whole blood and tissue pieces. BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency. In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity bd-e2bet.com/login infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
- BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency.
- The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research.
- Elevate your spectral data with built‑in standardization
- Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news.
GE HealthCare
Backed by cutting-edge technology and more than 50 years of flow cytometry expertise A comprehensive suite of trusted products, integrated solutions, useful tools and a wealth of information to advance your flow cytometry applications. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. The name “embecta” represents the company’s commitment to people living with diabetes and its corporate heritage, with the “em-” prefix evoking empathy for people living with diabetes and the empowerment of the new company and the “bect” imbibed from Becton. Embecta Corporation is a standalone public company focused on diabetes care.
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations. The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes. In certain places, BD Medical also offers consulting and analytics related services.
BD announced that it notified customers about the recall by letter and has been working with the U.S. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death.
Becton Dickinson’s shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.
Watch Jacopo Larcher climb Bon Voyage (9a/5.14d), the hardest trad route in France. Watch Connor Herson establish the world’s hardest trad climb. An interactive tool containing key cell information to help plan your flow cytometry experiments.
And read his essay on the future of cutting-edge trad climbing. Focused on comfort and freedom of movement, built for the climbing life. Our Bottom Line Collection combines features built for climbing with style that transcends the crag. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices. Core to climbing, core to Black Diamond, and engineered to send.